Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 16/20 | 0.68 |
| ▸ | PI4KA | P42356 | 2/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.53 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31216400 | 1.00 | MAP4K4 (0.68) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28001861 | 0.85 | MAP4K4 (0.74) | MAP4K4 | |
| SCHEMBL7376295 | 0.84 | MAP4K4 (0.54) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL15587433 | 0.81 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL29713890 | 0.79 | MAP4K4 (0.66) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4692556 | 0.79 | MAP4K4 (0.66) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6956273 | 0.79 | HTT (0.53) | MAP4K4 | |
| Toluene SCHEMBL27551696 | 0.79 | MAP4K4 (0.61) | MAP4K4PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30943393 | 0.79 | MAP4K4 (0.61) | MAP4K4 | |
| Water SCHEMBL28851833 | 0.78 | MAP4K4 (0.64) | MAP4K4PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285628-A | Compounds for the treatment and prophylaxis of respiratory syncytial virus infection diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118852149-A | Compound for treating or preventing RSV virus diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-04-26 | — | — | US | disclosed |
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3811974-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | Infinity Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-25 | — | — | US | disclosed |
| WO-2020239999-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| WO-2004031145-A2 | LACTAM-CONTAINING DIAMINOALKYL, BETA-AMINOACIDS, ALPHA-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003047520-A2 | SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| US-4543356-A | Quinazoline derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-09-24 | — | — | US | disclosed |
| EP-0030156-B1 | QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-21 | — | — | EP | disclosed |
| US-4429126-A | ANTIASTHMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-01-31 | — | — | US | disclosed |
| US-4377580-A | ANTIALLERGENIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-03-22 | — | — | US | disclosed |
| EP-0030156-A1 | Quinazoline derivatives, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | ERBB2, EGFR, ERBB4 | MAP4K4 349/4885PI4KA 273/4885PI4K2B 354/4885 |
| US-20210085656-A1 | SUBSTITUTED DIHYDROIMIDAZOPYRIDINEDIONES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | MAP4K4 9/4885PI4KA 151/4885PI4K2B 171/4885 |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | MKNK1, MKNK2, MAP4K5 | MAP4K4 9/4885PI4KA 151/4885PI4K2B 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.